KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Ginkgo Bioworks Holdings (DNA) over the last 6 years, with Q3 2025 value amounting to $17.8 million.

  • Ginkgo Bioworks Holdings' Share-based Compensation rose 2876.94% to $17.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.1 million, marking a year-over-year decrease of 3977.12%. This contributed to the annual value of $112.3 million for FY2024, which is 5113.01% down from last year.
  • Per Ginkgo Bioworks Holdings' latest filing, its Share-based Compensation stood at $17.8 million for Q3 2025, which was up 2876.94% from $22.2 million recorded in Q2 2025.
  • Over the past 5 years, Ginkgo Bioworks Holdings' Share-based Compensation peaked at $1.6 billion during Q4 2021, and registered a low of $118000.0 during Q1 2021.
  • Its 5-year average for Share-based Compensation is $207.3 million, with a median of $40.8 million in 2024.
  • Per our database at Business Quant, Ginkgo Bioworks Holdings' Share-based Compensation soared by 134842203.39% in 2021 and then tumbled by 9320.23% in 2022.
  • Quarter analysis of 5 years shows Ginkgo Bioworks Holdings' Share-based Compensation stood at $1.6 billion in 2021, then crashed by 93.2% to $108.2 million in 2022, then crashed by 60.4% to $42.8 million in 2023, then tumbled by 52.0% to $20.6 million in 2024, then dropped by 13.23% to $17.8 million in 2025.
  • Its Share-based Compensation stands at $17.8 million for Q3 2025, versus $22.2 million for Q2 2025 and $20.4 million for Q1 2025.